RA'ANANA, Israel, Jan. 21,
2025 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or
the "Company"), a leader in life-support technology innovation, has
announced the appointment of Mr. Tal
Parnes as the new chairman of the board of directors,
effective February 1, 2025.
Mr. Parnes brings a wealth of experience and expertise to his
new role at Inspira. With a distinguished career spanning over
three decades in the technology sector, with a special focus in the
medical technology and pharmaceutical industries, Mr. Parnes has
consistently demonstrated exceptional leadership and strategic
vision.
As a serial entrepreneur, Parnes has demonstrated his ability to
drive innovation and growth across various high-tech sectors,
including medical technology, communications and defense. Mr.
Parnes is familiar with the Company and its technology, having
served as an independent director of the Company since July 2021.
Mr. Parnes is a veteran executive in the medical technology
industry. He co-founded and is the former chief executive officer
and president at Zuta-Core Ltd. and HQL Pharmaceuticals Ltd. Mr.
Parnes also served as chief operating officer at Silynx
Communications Inc. as a vice president of operations at Wavion
Inc. and Atrica Ltd. He also served as chief financial officer and
director of business development of Printlife Ltd.
The appointment of Mr. Parnes as chairman of the board of
directors will enhance the Company's leadership. Mr. Parnes'
unwavering commitment to integrating his vast knowledge of emerging
technologies and market trends will be invaluable. Mr. Parnes'
leadership will not only refine the Company's strategic vision but
also bolster the Company's competitive advantage in the market,
positioning the Company for sustainable success in the future. The
Company is eager to harness Mr. Parnes' insights and experience as
the Company reaches new heights.
The Company would like to thank Prof. Benad Goldwasser, MD, for
his leadership role as chairman of the board of directors since
2021. The Company extends its gratitude for his numerous activities
and contributions to the Company, spanning business, medical, and
administrative aspects. Prof. Goldwasser provided invaluable
support during the Company's Nasdaq Capital Market listing and
leveraged his extensive network of connections from his years of
experience. The Company accepted Prof. Goldwasser's resignation
from his position, which was due to personal reasons.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to revolutionize
the $19 billion mechanical ventilation market. With 20
million intensive care unit patients with acute respiratory failure
each year, many of whom rely on mechanical ventilators, the INSPIRA
ART offers a potential alternative by elevating and stabilizing
decreasing oxygen saturation levels in minutes without a
ventilator, with patients being awake during treatment. The INSPIRA
ART is being equipped with a clip-on HYLA™ blood sensor, a
real-time continuous blood monitoring technology, aiming to alert
physicians of changes in a patient's condition without the need for
intermittent actual blood samples, aiming to support physicians in
making informed decisions.
In June and July 2024,
respectively, the Company's INSPIRA™ ART100 system has
obtained FDA 510(k) clearance for use in CBP procedures, along with
the Israeli AMAR certification for both Extra-Corporeal Membrane
Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery
System, and HYLA™ blood sensor, are currently being designed and
developed, and have not yet been tested or used in humans nor
approved by any regulatory entity.
For more information, please visit our corporate website
at https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements are based on the current expectations of
the management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
For example, the Company is using forward-looking statements when
it discusses the potential positive outcome of Mr. Parnes'
appointment. These forward-looking statements and their
implications are based solely on the current expectations of the
Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website at www.sec.gov.
Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Photo -
https://mma.prnewswire.com/media/2602501/Tal_Parnes.jpg
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inspira-announces-the-appointment-of-tal-parnes-as-the-new-chairman-of-the-board-bringing-vast-experience-in-the-medical-technology-and-pharmaceutical-sectors-302356143.html
SOURCE Inspira Technologies